Navigation Links
Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
Date:10/4/2011

INDIANAPOLIS, Oct. 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it is improving its environmental footprint by achieving two of the company's three environmental goals ahead of schedule. Through the end of 2010, the company reduced the amount of waste sent to landfills by about 50 percent and has reduced its water intake by more than 30 percent. Lilly remains on track to meet its energy goal. Lilly has improved the energy efficiency of its operations by almost 12 percent while greenhouse gas emissions have been reduced by more than 9 percent through 2010.  

The goals were established for a five-year period beginning in 2008, using 2007 performance as a baseline. The company had aimed for a 40 percent reduction in waste to landfills and a 25 percent reduction in water intake by 2013. By 2013, the company hopes to achieve a 15 percent improvement in energy efficiency and in reducing greenhouse gas emissions.

"Through the efforts of our employees worldwide, we're making great progress to lessen our environmental impact in the communities where we operate," said Steve Gillman, vice president of health, safety, and environment. "We take this responsibility seriously and remain committed to finding more ways to use resources more efficiently and improve our performance."

Lilly has been able to avoid disposing of waste by reducing, reusing, and recycling in its business operations. Such efforts have resulted in only 10 percent of waste being sent to landfills last year. The company has six locations that have achieved a zero-landfill status including facilities in research, manufacturing and distribution.

Overall in 2010, the company reused approximately 65 percent of its waste. For example, mycelia, a solid material left after a fermentation process, is being used as a soil conditioner on farmland to improve plant growth. And spent urea, a material used in insulin production, is being used as an ingredient in fertilizer manufacturing.

In 2007, Lilly's water intake was almost 20 billion liters for the company's facilities worldwide. Last year the total amount of water brought into the company's facilities had been reduced to 13.3 billion liters. Water intake reduction was achieved by improving the efficiency of operations, identifying and repairing leaks in water systems, improving purified-water production, and treating and reusing water in cooling tower systems.

In response to meeting these goals ahead of schedule, the company has established new waste and water goals for a two-year period, 2011-2013, using 2010 results as a baseline. The new goals are:

Water – reduce water intake by five percent

Waste – reduce the amount of waste sent to landfills by 20 percent, with an ultimate goal of zero-landfill

"While we're making great progress, we know we still have much more work to do," Gillman said. "We'll continue to work aggressively to achieve our environmental goals and reduce our footprint."

Today's announcement comes in advance of Lilly's Global Day of Service being held this week on October 6. An estimated 24,000 employees from 34 countries will participate in Global Day Service activities focused on improving communities worldwide including projects that will enhance outdoor spaces. In Indianapolis, where Lilly is headquartered, Global Day of Service volunteers, will plant 3,000 trees and 14,000 plants to refresh parks, trails and neighborhoods, in an effort to improve green space and encourage more people to get out, get active, and enjoy the many natural health benefits associated with outdoor activities.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. CR-LLY

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):